Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cytosine deaminase from Escherichia coli is a microbial enzyme that catalyzes the conversion of cytosine to uracil, which is a key reaction in the pyrimidine salvage pathway, allowing the microorganism to utilize cytosine as a nitrogen source. The enzyme is structurally characterized by an (αβ)\_8\_ barrel fold, contains a catalytic metal ion (usually iron), and is not present in multicellular eukaryotes[1][2]. Cytosine deaminase has gained attention in biotechnology and medicine because it enables tumors engineered to express it to convert the antifungal prodrug 5-fluorocytosine into the anticancer agent 5-fluorouracil, resulting in a localized cytotoxic effect for cancer gene therapy ("suicide gene" approach)[5][1]. In addition to cytosine, the enzyme can also deaminate mutagenic bases such as isoguanine[3]. It is not a human protein, reducing the risk of immune tolerance and conferring specificity in targeted applications.
Hydrolytic deamination of cytosine to uracil; Bioactivation of 5-fluorocytosine to cytotoxic 5-fluorouracil for use in suicide gene therapy[5][6][2]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cytosine deaminase (Escherichia coli) (CD or CDA).